MARKET

IBIO

IBIO

Ibio
NASDAQ
1.760
+0.020
+1.15%
After Hours: 1.800 +0.04 +2.27% 19:19 03/27 EDT
OPEN
1.710
PREV CLOSE
1.740
HIGH
1.880
LOW
1.695
VOLUME
1.27M
TURNOVER
--
52 WEEK HIGH
4.860
52 WEEK LOW
0.5562
MARKET CAP
60.80M
P/E (TTM)
-1.3980
1D
5D
1M
3M
1Y
5Y
1D
Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater
TipRanks · 14h ago
Top Ibio Insider Quietly Ups Stake in Bold New Bet
TipRanks · 1d ago
iBio Chief Legal Officer Marc Banjak acquires common shares; $23,028 value
Reuters · 1d ago
iBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating
TipRanks · 2d ago
Top Ibio Insiders Quietly Load Up on Shares in Bold Confidence Move
TipRanks · 5d ago
iBio CFO Felipe Duran buys USD 50,000 of common shares
Reuters · 5d ago
iBio CEO and CSO Martin Brenner acquires USD 24,919 of common shares
Reuters · 5d ago
Weekly Report: what happened at IBIO last week (0316-0320)?
Weekly Report · 5d ago
More
About IBIO
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.

Webull offers Ibio Inc stock information, including NASDAQ: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.